Nasdaq Combined Compos (COMPX.US)

Close: 12 355.00 (+156.37), Dec 1, 2020
Positive

Medium risk

Automatic technical analysis. Medium term, Dec 1, 2020

Nasdaq Combined Composite Index is in a rising trend channel in the medium long term. This shows that investors over time have bought the index at higher prices and indicates good development for the market. The index has broken up through the resistance at points 12000. This predicts a further rise. RSI above 70 shows that the index has strong positive momentum in the short term. Investors have steadily paid more to buy the index, which indicates increasing optimism and that the price will continue to rise. However, particularly for big stocks, high RSI may be a sign that the stock is overbought and that there is a chance of a reaction downwards. The index is overall assessed as technically positive for the medium long term.

Recommendation one to six months: Positive (Score: 87)

Period  
Vol.bal. Volatility Liquidity +/- %
1 day-1.25%0.00+1.28%
5 days0.003.81%0.00+3.99%
22 days0.0010.49%0.00+10.46%
66 days0.0022.90%0.00+6.28%

More analyses of Nasdaq Combined Composite Index

chart Nasdaq Combined Composite Index (COMPX) Candlesticks 22 Days
Candlesticks
chart Nasdaq Combined Composite Index (COMPX) Short term
Short term: Positive
chart Nasdaq Combined Composite Index (COMPX) Medium term
Medium term: Positive
chart Nasdaq Combined Composite Index (COMPX) Long term
Long term: Positive
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK
Free Trial Now